Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs

Insulin Aspart ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Biphasic Insulin ◽

Oral Antidiabetic ◽

Biphasic Insulin Aspart 30

Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy

Clinical Therapeutics ◽

10.1016/s0149-2918(03)90095-6 ◽

2003 ◽

Vol 25 (12) ◽

pp. 3109-3123 ◽

Cited By ~ 17

Author(s):

Itamar Raz ◽

Ulrik Mouritzen ◽

Julius Vaz ◽

Tommy Hershkovitz ◽

Julio Wainstein ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Insulin Aspart ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30

Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L randomized clinical trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14005 ◽

2020 ◽

Vol 22 (S4) ◽

pp. 3-13 ◽

Cited By ~ 3

Author(s):

Hideaki Kaneto ◽

Akane Takami ◽

Robert Spranger ◽

Atsushi Amano ◽

Daisuke Watanabe ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v3/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v2/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Review for "Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi 1:1) in Japanese patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs: A randomized, 26-week, open-label, multicenter study: The L"

10.1111/dom.14036/v1/review1 ◽

2019 ◽

Author(s):

Graydon Meneilly

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Open Label ◽

Decision letter for "Efficacy and safety of insulin glargine/lixisenatide fixed‐ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP‐L Randomized Clinical Trial"

10.1111/dom.14005/v1/decision1 ◽

2020 ◽

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Clinical Trial ◽

Fixed Ratio ◽

Japanese Patients ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts)

Diabetes Obesity and Metabolism ◽

10.1111/j.1463-1326.2007.00796.x ◽

2009 ◽

Vol 11 (1) ◽

pp. 27-32 ◽

Cited By ~ 24

Author(s):

P. Raskin ◽

G. Matfin ◽

S. L. Schwartz ◽

L. Chaykin ◽

P.-L. Chu ◽

...

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Insulin Aspart ◽

Biphasic Insulin Aspart ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30 ◽

Oral Agents ◽

Pioglitazone Treatment

Comparative Efficacy and Safety of Empagliflozin with Other Oral Antidiabetic Drugs for the Second Line Treatment of Type 2 Diabetes Mellitus

Value in Health ◽

10.1016/j.jval.2014.08.631 ◽

2014 ◽

Vol 17 (7) ◽

pp. A333

Author(s):

K. Thorlund ◽

G. Siliman ◽

S. Eapen ◽

S. Lund ◽

R. Palencia

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Line Treatment ◽

Second Line ◽

Efficacy And Safety ◽

Oral Antidiabetic Drugs ◽

Comparative Efficacy ◽

Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: A double-blind crossover study in adults with type 2 diabetes mellitus

Clinical Therapeutics ◽

10.1016/s0149-2918(02)85129-3 ◽

2002 ◽

Vol 24 (4) ◽

pp. 530-539 ◽

Cited By ~ 64

Author(s):

Paul T. McSorley ◽

Patrick M. Bell ◽

Lisbeth Vestergård Jacobsen ◽

Allan Kristensen ◽

Anders Lindholm

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Insulin Aspart ◽

Double Blind ◽

Biphasic Insulin ◽

Biphasic Insulin Aspart 30 ◽

Blind Crossover Study ◽

Double Blind Crossover Study

Improved Glycaemic Control with Biphasic Insulin Aspart 30 in Type 2 Diabetes Patients Failing Oral Antidiabetic Drugs: PRESENT Study Results

Archives of Drug Information ◽

10.1111/j.1753-5174.2008.00015.x ◽

2009 ◽

Vol 2 (2) ◽

pp. 23-33 ◽

Cited By ~ 5

Author(s):

Serdar Güler ◽

Surendra Kumar Sharma ◽

Majeed Almustafa ◽

Chong Hwa Kim ◽

Sami Azar ◽

...

Keyword(s):

Type 2 Diabetes ◽

Glycaemic Control ◽

Insulin Aspart ◽

Oral Antidiabetic Drugs ◽

Biphasic Insulin ◽

Oral Antidiabetic ◽

Biphasic Insulin Aspart 30 ◽

Study Results ◽

Improved Glycaemic Control